SGHT

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.

Wall Street analysts forecast SGHT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGHT is 5.17 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sight Sciences Inc revenue for the last quarter amounts to 19.91M USD, decreased -1.25 % YoY.

Sight Sciences Inc. EPS for the last quarter amounts to -0.16 USD, decreased -27.27 % YoY.

Sight Sciences Inc (SGHT) has 216 emplpoyees as of December 15 2025.

Today SGHT has the market capitalization of 428.26M USD.